LLY Jan 2025 330.000 put
| Previous close | 6.24 |
| Open | 6.24 |
| Bid | 3.40 |
| Ask | 10.90 |
| Strike | 330.00 |
| Expiry date | 2025-01-17 |
| Day's range | 6.24 - 6.24 |
| Contract range | N/A |
| Volume | |
| Open interest | 128 |
ZacksLilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
ZacksAltimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Motley Fool1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Dividend stocks have a well-earned reputation for outperformance. Modern portfolio theory (MPT), however, indicates that growth investors should strictly adhere to a couple of critical guidelines when picking dividend stocks for their portfolios. Among the most important guideposts recommended by the peer-reviewed MPT literature are selecting stocks with dividends lower than the average of the benchmark S&P 500 index; selecting stocks with premium valuations and a track record of positive annual returns; and selecting stocks in fast-growing sectors like healthcare or technology.
